Literature DB >> 33047336

Predictive value of tumor-infiltrating lymphocytes for response to neoadjuvant chemotherapy and breast cancer prognosis.

Xiaomin Li1, Qiuwen Tan2, Hongjiang Li2, Xiaoqin Yang2.   

Abstract

BACKGROUND: Tumor-infiltrating lymphocytes (TILs) are predictive for the response to neoadjuvant chemotherapy (NAC) of breast cancer. However, little is known about the predictive value of TILs for axillary lymph node involvement after NAC.
METHODS: We analyzed 282 breast cancer patients who were operated following NAC and curative surgery from 2008 to 2018. TILs were assessed in core needle biopsies before NAC, and the biopsies were divided into three groups: low (0%-10% immune cells in stromal tissue within the tumor), intermediate (11%-59%), and high (≥60%). The patients were followed for an average of 63 months (range, 2-116 months). We analyzed retrospectively the predictive value of TILs for the response to NAC, including pathological complete response (pCR) and axillary lymph node involvement (positive lymph node ratio (LNR; the ratio of the number of nodes involved to the total number of nodes dissected)). The prognostic values of TILs and LNR were assessed.
RESULTS: A pCR was achieved in 27 of 188 patients (14.4%) in the low-TIL group, in 14 of 57 patients (24.6%) in the intermediate-TIL group, and in 13 of 37 (35.1%) in the high-TIL group (p = .007). Among patients who underwent axillary lymph node dissection after NAC, patients with high TILs had lower LNR (p = 0021) compared with the other groups. Kaplan-Meier analysis showed that overall survival (OS; p < .001) and disease-free survival (p < .001) were significantly longer for patients with low LNR (≤0.2). TILs were positively correlated with disease-free survival (p = .028), but TILs did not correlate with OS (p = .171). Moreover, by multivariable analysis, LNR independently affected disease-free survival (p < .001).
CONCLUSIONS: TILs may be predictive for pCR rate, postoperative residual lymph node involvement, and disease-free survival of breast cancer patients. High TILs may suggest favorable outcomes.
© 2020 Wiley Periodicals LLC.

Entities:  

Keywords:  disease-free survival; positive lymph node ratio; triple-negative breast cancer

Mesh:

Year:  2020        PMID: 33047336     DOI: 10.1002/jso.26252

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  4 in total

1.  Efficacy and prognostic factors of neoadjuvant chemotherapy for triple-negative breast cancer.

Authors:  Feng Ding; Ru-Yue Chen; Jun Hou; Jing Guo; Tian-Yi Dong
Journal:  World J Clin Cases       Date:  2022-04-26       Impact factor: 1.534

2.  HER2-low breast cancer shows a lower immune response compared to HER2-negative cases.

Authors:  Nadine S van den Ende; Marcel Smid; Annemieke Timmermans; Johannes B van Brakel; Tim Hansum; Renée Foekens; Anita M A C Trapman; Bernadette A M Heemskerk-Gerritsen; Agnes Jager; John W M Martens; Carolien H M van Deurzen
Journal:  Sci Rep       Date:  2022-07-28       Impact factor: 4.996

3.  Based on clinical Ki-67 expression and serum infiltrating lymphocytes related nomogram for predicting the diagnosis of glioma-grading.

Authors:  Zhi Zhang; Weiguo Gu; Mingbin Hu; Guohua Zhang; Feng Yu; Jinbiao Xu; Jianxiong Deng; Linlin Xu; Jinhong Mei; Chunliang Wang; Feng Qiu
Journal:  Front Oncol       Date:  2022-08-25       Impact factor: 5.738

4.  Predictive Value of Pretreatment Peripheral Neutrophil-to-Lymphocyte Ratio for Response to Neoadjuvant Chemotherapy and Breast Cancer Prognosis.

Authors:  Xiaomin Li; Qiuwen Tan; Hongjiang Li; Xiaoqin Yang
Journal:  Cancer Manag Res       Date:  2021-07-28       Impact factor: 3.989

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.